IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis

Sponsor
Pfizer
Study ID
NCT03981900
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Regarding Tofacitinib, newly introduced on the market, few data on drug retention and no data on the factors predictive of Tofacitinib drug survival in patients with RA are available. Therefore, the primary objective of the DeFacTo study will be to identify the factors predictive of Tofacitinib drug survival in patients with RA. As secondary objectives, the impact of behavioural strategies on drug survival and other clinical parameters as well as Tofacitinib effectiveness and tolerability will be studied under real-life conditions of use in French patients with RA.

Key Dates

Start date
Jan 4, 2019
Status verified
Jun 2024
Primary completion
Feb 6, 2023
Completion
Feb 6, 2023

Study Design

Enrollment
314 participants (actual)

Arms

  • Arm: Rheumatoid arthritis
    All participants with a diagnosis of moderate to severe active rheumatoid arthritis and treated with Tofacitinib

Primary Outcome Measure

Duration of Tofacitinib Drug Survival [ Time Frame: Date of initiation of study drug treatment up to date of permanent drug discontinuation or date of censoring (up to a maximum of 48 months) ]

Related Studies